Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

PMID:
31484791
2.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).

Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM, Chugh R, Milhem MM, Hirbe AC, Kim A, Turpin B, Pressey JG, Dombi E, Jayaprakash N, Helman LJ, Onwudiwe N, Cichowski K, Perentesis JP.

Sarcoma. 2019 Jul 24;2019:7656747. doi: 10.1155/2019/7656747. eCollection 2019.

3.

KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.

Zhang C, D'Alessandro A, Wellendorf AM, Mohmoud F, Serrano-Lopez J, Perentesis JP, Komurov K, Alexe G, Stegmaier K, Whitsett JA, Grimes HL, Cancelas JA.

Oncotarget. 2018 Jul 3;9(51):29665-29679. doi: 10.18632/oncotarget.25667. eCollection 2018 Jul 3.

4.

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.

Meyer SE, Muench DE, Rogers AM, Newkold TJ, Orr E, O'Brien E, Perentesis JP, Doench JG, Lal A, Morris PJ, Thomas CJ, Lieberman J, McGlinn E, Aronow BJ, Salomonis N, Grimes HL.

J Exp Med. 2018 Aug 6;215(8):2115-2136. doi: 10.1084/jem.20171312. Epub 2018 Jul 11.

5.

Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN.

Weber DC, Habrand JL, Hoppe BS, Hill Kayser C, Laack NN, Langendijk JA, MacDonald SM, McGovern SL, Pater L, Perentesis JP, Thariat J, Timmerman B, Yock TI, Mahajan A.

Radiother Oncol. 2018 Jul;128(1):44-55. doi: 10.1016/j.radonc.2018.05.020. Epub 2018 Jun 21. Review.

PMID:
29937209
6.

An Update From the Pediatric Proton Consortium Registry.

Hess CB, Indelicato DJ, Paulino AC, Hartsell WF, Hill-Kayser CE, Perkins SM, Mahajan A, Laack NN, Ermoian RP, Chang AL, Wolden SL, Mangona VS, Kwok Y, Breneman JC, Perentesis JP, Gallotto SL, Weyman EA, Bajaj BVM, Lawell MP, Yeap BY, Yock TI.

Front Oncol. 2018 May 24;8:165. doi: 10.3389/fonc.2018.00165. eCollection 2018.

7.

Viral surveillance using PCR during treatment of AML and ALL.

Dixon SB, Lane A, O'Brien MM, Burns KC, Mangino JL, Breese EH, Absalon MJ, Perentesis JP, Phillips CL.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26752. Epub 2017 Aug 9.

PMID:
28792686
8.

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26565. Epub 2017 Apr 27.

9.

Significant and Sustained Reduction in Chemotherapy Errors Through Improvement Science.

Weiss BD, Scott M, Demmel K, Kotagal UR, Perentesis JP, Walsh KE.

J Oncol Pract. 2017 Apr;13(4):e329-e336. doi: 10.1200/JOP.2017.020842. Epub 2017 Mar 4.

PMID:
28260404
10.

Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.

Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA.

Br J Clin Pharmacol. 2017 May;83(5):1097-1107. doi: 10.1111/bcp.13181. Epub 2016 Dec 20.

11.

Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs).

Bukowinski AJ, Burns KC, Parsons K, Perentesis JP, O'Brien MM.

Semin Oncol Nurs. 2015 Aug;31(3):216-26. doi: 10.1016/j.soncn.2015.05.003. Epub 2015 May 7. Review.

PMID:
26210200
12.

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP.

Pediatr Blood Cancer. 2015 Oct;62(10):1739-46. doi: 10.1002/pbc.25594. Epub 2015 Jul 7.

PMID:
26153194
13.

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.

Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM.

Clin Cancer Res. 2015 Apr 1;21(7):1558-65. doi: 10.1158/1078-0432.CCR-14-0595. Epub 2014 Dec 2.

14.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

15.

AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI.

Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25.

16.

A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.

Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM.

Pediatr Blood Cancer. 2014 Jul;61(7):1246-51. doi: 10.1002/pbc.25023. Epub 2014 Mar 24.

17.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.

18.

Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.

Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP.

Br J Haematol. 2013 May;161(3):406-10. doi: 10.1111/bjh.12268. Epub 2013 Feb 23.

PMID:
23432727
19.

Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.

Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S; COG Acute Myeloid Leukemia Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):964-71. doi: 10.1002/pbc.24432. Epub 2012 Dec 19. Review.

20.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

21.

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL.

J Clin Oncol. 2012 Aug 10;30(23):2919-28. doi: 10.1200/JCO.2011.39.7356. Epub 2012 Jul 9.

22.

Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.

Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JA.

Blood. 2012 Jul 26;120(4):800-11. doi: 10.1182/blood-2011-06-361709. Epub 2012 Jun 12.

23.

Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor.

Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S.

J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2. doi: 10.1097/MPH.0b013e31820c3403.

PMID:
21646919
24.

Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods.

Davies SM, Perentesis JP.

Pediatr Blood Cancer. 2011 Jun;56(6):895-6. doi: 10.1002/pbc.23093. No abstract available.

PMID:
21394889
25.

Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.

Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, Horn BN, Margolis DA, Perentesis JP, Sanders JE, Schultz KR, Seber A, Woods WG, Eapen M.

Biol Blood Marrow Transplant. 2011 May;17(5):723-8. doi: 10.1016/j.bbmt.2010.08.016. Epub 2010 Oct 8.

26.

MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM.

Pediatr Blood Cancer. 2010 Aug;55(2):248-53. doi: 10.1002/pbc.22519.

27.

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC.

Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.

28.

FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report.

Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM.

Clin Cancer Res. 2008 Dec 1;14(23):7896-9. doi: 10.1158/1078-0432.CCR-08-0418.

29.

DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.

Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group.

Leukemia. 2008 Feb;22(2):265-72. Epub 2007 Nov 22.

30.

Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors.

Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR.

Bone Marrow Transplant. 2006 Jan;37(2):175-81.

PMID:
16273111
31.

XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report.

Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group.

Blood. 2006 Jan 1;107(1):39-45. Epub 2005 Sep 8.

32.

Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Shu XO, Perentesis JP, Wen W, Buckley JD, Boyle E, Ross JA, Robison LL; Children's Oncology Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1230-5.

33.

RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.

Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M, Sather HN, Gaynon P, Kiffmeyer W, Envall-Fox J, Robison LL.

Leukemia. 2004 Apr;18(4):685-92.

PMID:
14990973
34.

Osteosarcoma in the first decade of life.

Nagarajan R, Weigel BJ, Thompson RC, Perentesis JP.

Med Pediatr Oncol. 2003 Nov;41(5):480-3. No abstract available.

PMID:
14515397
35.

Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?

Thornley I, Perentesis JP, Davies SM, Smith FO, Champagne M, Lipton JM.

Med Pediatr Oncol. 2003 Aug;41(2):115-7. No abstract available.

PMID:
12825214
36.
37.

Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia.

Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, Robison LL, Perentesis JP.

Blood. 2002 Jul 1;100(1):67-71.

38.

Targeted therapies for high-risk acute myeloid leukemia.

Perentesis JP, Sievers EL.

Hematol Oncol Clin North Am. 2001 Aug;15(4):677-701, viii-ix. Review.

PMID:
11676279
39.

Genetic predisposition and treatment-related leukemia.

Perentesis JP.

Med Pediatr Oncol. 2001 May;36(5):541-8. Review.

PMID:
11340609
40.

Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia.

Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA, Ross JA, Perentesis JP.

J Clin Oncol. 2001 Mar 1;19(5):1279-87.

PMID:
11230469
41.

Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.

Shao Y, Warman BE, Perentesis JP.

Methods Mol Biol. 2001;166:31-53. Review. No abstract available.

PMID:
11217375
42.

Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study.

Davies SM, Robison LL, Buckley JD, Radloff GA, Ross JA, Perentesis JP.

Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):563-6.

43.

Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors.

Ross JA, Schmidt PT, Perentesis JP, Davies SM.

Cancer. 1999 Mar 15;85(6):1389-94.

PMID:
10189147
44.

Accuracy of DNA amplification from archival hematological slides for use in genetic biomarker studies.

Boyle EB, Steinbuch M, Tekautz T, Gutman JR, Robison LL, Perentesis JP.

Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1127-31.

45.

In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.

Perentesis JP, Gunther R, Waurzyniak B, Yanishevski Y, Myers DE, Ek O, Messinger Y, Shao Y, Chelstrom LM, Schneider E, Evans WE, Uckun FM.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2217-27.

46.

Coinheritance of alpha-thalassemia-1 and hemoglobin E/beta zero-thalassemia: practical implications for neonatal screening and genetic counseling.

Krishnamurti L, Chui DH, Dallaire M, LeRoy B, Waye JS, Perentesis JP.

J Pediatr. 1998 May;132(5):863-5.

PMID:
9602201
47.

Why is age such an important independent prognostic factor in acute lymphoblastic leukemia?

Perentesis JP.

Leukemia. 1997 May;11 Suppl 4:S4-7. Review.

PMID:
9179272
48.

A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.

Bendel AE, Shao Y, Davies SM, Warman B, Yang CH, Waddick KG, Uckun FM, Perentesis JP.

Leuk Lymphoma. 1997 Apr;25(3-4):257-70.

PMID:
9168436
49.

Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.

Perentesis JP, Bendel AE, Shao Y, Warman B, Davies SM, Yang CH, Chandan-Langlie M, Waddick KG, Uckun FM.

Leuk Lymphoma. 1997 Apr;25(3-4):247-56.

PMID:
9168435

Supplemental Content

Loading ...
Support Center